Article Data

  • Views 498
  • Dowloads 133

Original Research

Open Access

Diagnostic value of cancer antigen 72-4 for ovarian cancer: a meta-analysis

  • Chuntao Wu1,*,
  • Jiliang Wang2,*,
  • Li Wang3
  • Jianfeng Shi4
  • Wanhua Xue5,*,

1Department of ICU, the Third Hospital of Hebei Medical University, Shijiazhuang

2Department of Clinical Laboratory, Shengli Oilfield Central Hospital, Dongying

3Department of Clinical Laboratory, Jinan Infectious Disease Hospital, Jinan

4Department of Clinical Laboratory, Yantai Infectious Disease Hospital, Yantai

5Department of Clinical Laboratory, Dezhou People’s Hospital, Dezhou (China)

DOI: 10.12892/ejgo3953.2018 Vol.39,Issue 2,April 2018 pp.271-276

Published: 10 April 2018

*Corresponding Author(s): Wanhua Xue E-mail: yspaxwh@126.com

Abstract

Objective: This meta-analysis was aimed to evaluate the diagnostic value of CA72-4 as a biomarker in diagnosing ovarian cancer (OC). Materials and Methods: Relevant studies were retrieved through searching PubMed and Embase, up to June 2016. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR), as well as corresponding 95% confidence intervals (CIs) were calculated. The summary receiver operating characteristics curve (SROC) was drawn and the area under SROC (AUC) was calculated. Results: A total of 11 relevant literatures with 891 OC cases and 1,623 controls were identified. The overall estimates of CA72-4 are shown as the follows: sensitivity = 0.49 (95% CI: 0.46−0.53), specificity = 0.89 (95% CI: 0.87−0.90, PLR = 4.62, (95% CI: 2.91−7.34), NLR = 0.52 (95% CI: 0.40−0.67), DOR = 9.17 (95% CI = 4.67−18.03), and AUC = 0.8384 ± 0.1106. Subgroup analyses with four studies (in which 3.8 U/mL was used as cutoff value) showed the slightly higher sensitivity (0.60, 95% CI = 0.54−0.65), specificity (0.93, 95% CI = 0.91−0.94,), PLR (8.27, 95% CI = 6.06−11.27), DOR (20.91, 95% CI = 12.43−35.19), AUC (0.8997 ± 0.1265), and lower NLR (0.42, 95% CI = 0.33−0.52), compared with that in overall analyses. Conclusions: CA72-4 is a biomarker for diagnosing OC with high specificity but low sensitivity. The most appropriate cutoff value should be further explored in further studies.

Keywords

Ovarian cancer; Cancer antigen 72-4; Diagnostic marker; Meta-analysis

Cite and Share

Chuntao Wu,Jiliang Wang,Li Wang,Jianfeng Shi,Wanhua Xue. Diagnostic value of cancer antigen 72-4 for ovarian cancer: a meta-analysis. European Journal of Gynaecological Oncology. 2018. 39(2);271-276.

References

[1] Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A.: “Global cancer statistics, 2012”. CA Cancer J. Clin., 2015, 65, 87.

[2] Siegel R.L., Miller K.D., Jemal A.: “Cancer statistics, 2015”. CA Cancer J. Clin., 2015, 65, 5.

[3] Johnson V.G., Schlom J., Paterson A.J., Bennett J., Magnani J.L., Colcher D.: “Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72. 3”. Cancer Res., 1986, 46, 850.

[4] Muraro R., Kuroki M., Wunderlich D., Poole D.J., Colcher D., Thor A., et al.: “Generation and characterization of B72. 3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen”. Cancer Res., 1988, 48, 4588.

[5] Thor A., Ohuchi N., Szpak C.A., Johnston W.W., Schlom J.: “Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72. 3”. Cancer Res., 1986, 46, 3118.

[6] Zheng C.X., Zhan W.H., Zhao J.Z., Zheng D., Wang D.P., He Y.L., et al.: “The prognostic value of preoperative serum levels of CEA, CA19-9 and CA72-4 in patients with colorectal cancer”. World J. Gastroenterol., 2001, 7, 431.

[7] Granato T., Midulla C., Longo F., Colaprisca B., Frati L., Anastasi E.: “Role of HE4, CA72. 4, and CA125 in monitoring ovarian cancer”. Tumor Biol., 2012, 33, 1335.

[8] Anastasi E., Manganaro L., Granato T., Benedetti Panici P., Frati L., Porpora M.G.: “Is CA72-4 a useful biomarker in differential diagnosis between ovarian endometrioma and epithelial ovarian cancer?” Dis. Markers, 2013, 35, 331.

[9] Tamakoshi K., Kikkawa F., Shibata K., Tomoda K., Obata N.H., Wakahara F., et al.: “Clinical value of CA125, CA19-9, CEA, CA72- 4, and TPA in borderline ovarian tumor”. Gynecol. Oncol., 1996, 62, 67.

[10] Lau J., Ioannidis J.P., Schmid C.H.: “Quantitative synthesis in systematic reviews”. Ann. Intern. Med., 1997, 127, 820.

[11] Zamora J., Abraira V., Muriel A., Khan K., Coomarasamy A.: “MetaDiSc: a software for meta-analysis of test accuracy data”. BMC Med. Res. Methodol., 2006, 6, 31.

[12] Ki-lan N.: “Meta-analysis: a quantitative approach of data pooling”. Pakistan Oral & Dent., 2000, 20, 214.

[13] Anastasi E., Granato T., Falzarano R., Storelli P., Ticino A., Frati L., et al.: “The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer”. J. Ovarian Res., 2013, 6, 44.

[14] Donach M., Yu Y., Artioli G., Banna G., Feng W., Bast Jr R.C., et al.: “Combined use of biomarkers for detection of ovarian cancer in high-risk women”. Tumor. Biol., 2010, 31, 209.

[15] Fayed S.T., Ahmad S.M., Kassim S.K., Khalifa A.: “The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer”. Dis. Markers, 1998, 14, 155.

[16] Gadducci A., Ferdeghini M., Prontera C., Moretti L., Mariani G., Bianchi R., et al.: “The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis”. Gynecol. Oncol., 1992, 44, 147.

[17] Moore R., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T., et al.: “The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass”. Gynecol. Oncol., 2008, 108, 402.

[18] Udagawa Y., Aoki D., Ito K., Uejima T., Uemura M., Nozawa S.: “Clinical characteristics of a newly developed ovarian tumour marker, galactosyltransferase associated with tumour (GAT)”. Eur. J. Cancer, 1998, 34, 489.

[19] Woolas R.P., Conaway M.R., Xu F., Jacobs I.J., Yu Y., Daly L., et al.: “Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses”. Gynecol. Oncol., 1995, 59, 111.

[20] Bian J., Li B., Kou X.J., Liu T.Z., Ming L.: “Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer”. Asian Pac. J. Cancer Prev., 2013, 14, 6241.

[21] Shadfan B.H., Simmons A.R., Simmons G.W., Ho A., Wong J., Lu K.H., et al.: “A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care”. Cancer Prev. Res., 2015, 8, 37.

[22] Simmons A.R., Clarke C.H., Badgwell D.B., Lu Z., Sokoll L.J., Lu K.H., et al.: “Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer”. Int. J. Gynecol. Cancer, 2016, 26, 1070-7.

[23] Nishida Y., Kohno K., Kawamata T., Morimitsu K., Kuwano M., Miyakawa I.: “Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4”. Gynecol. Oncol., 1995, 56, 357.

[24] Wang Z., Tian Y.P.: “Clinical value of serum tumor markers CA19- 9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma”. Mol. Clin. Oncol., 2014, 2, 265.

[25] Yang A.-P., Liu J., Lei H.-Y., Zhang Q.-W., Zhao L., Yang G.-H.: “CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer”. Clin. Chim. Acta, 2014, 437, 183.

[26] Louhimo J., Carpelan-Holmström M., Alfthan H., Stenman U.H., Järvinen H.J., Haglund C.: “Serum HCGβ, CA 72-4 and CEA are independent prognostic factors in colorectal cancer”. Int. J. Cancer, 2002, 101, 545.

[27] Louhimo J., Alfthan H., Stenman U.-H., Haglund C.: “Serum HCGβ and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer”. Oncology, 2004, 66, 126.

[28] Kobayashi H.: “The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer”. Nihon Sanka Fujinka Gakkai Zasshi, 1989, 41, 585.

[29] Nossov V., Amneus M., Su F., Lang J., Janco J.M.T., Reddy S.T., et al.: “The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?”. Am. JObstet. Gynecol., 2008, 199, 215.

[30] Bast R.C.: “Status of tumor markers in ovarian cancer screening”. J. Clin. Oncol., 2003, 21, 200s.

[31] Fayed S.T., Ahmad S.M., Kassim S.K., Khalifa A.: “The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer”. Dis. Markers, 1998, 14, 155.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top